CTOs on the Move

B-Bridge International

www.b-bridge.com

 
B-Bridge International is a Cupertino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.b-bridge.com
  • 20813 Stevens Creek Blvd Ste 200
    Cupertino, CA USA 95014
  • Phone: 408.252.6200

Executives

Name Title Contact Details

Similar Companies

Technologie BiolActis

Technologie BiolActis Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vaxxinity

Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health.

Relay Therapeutics

Relay Therapeutics is building the world`s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016. To date, Relay Therapeutics has raised $120M in financing from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), an affiliate of D.E. Shaw Research, Casdin Capital, EcoR1 Capital, Section 32 and Alexandria Venture Investments. Our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you`re creative, collaborative and passionate about making a difference in the lives of patients, join us!

Arizona Benefit Plans

Arizona Benefit Plans is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HilleVax

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.